|1.||Campion, Marilyn: 8 articles (03/2013 - 06/2010)|
|2.||Stolz, Leslie E: 7 articles (03/2015 - 01/2012)|
|3.||Pullman, William E: 7 articles (03/2013 - 06/2010)|
|4.||MacGinnitie, Andrew J: 6 articles (03/2015 - 03/2012)|
|5.||Bernstein, Jonathan A: 6 articles (03/2015 - 01/2010)|
|6.||Li, H Henry: 6 articles (03/2015 - 06/2010)|
|7.||Lumry, William R: 5 articles (03/2015 - 06/2010)|
|8.||Sheffer, Albert L: 5 articles (01/2014 - 08/2010)|
|9.||Riedl, Marc: 4 articles (03/2015 - 12/2010)|
|10.||Craig, Timothy J: 4 articles (03/2015 - 07/2011)|
01/01/2011 - "Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency."
03/01/2013 - "Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study."
01/01/2012 - "Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema."
07/01/2011 - "Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies."
08/05/2010 - "In this double-blind, placebo-controlled trial, patients with hereditary angioedema presenting with an acute attack were randomly assigned, in a 1:1 ratio, to receive subcutaneous ecallantide, at a dose of 30 mg, or placebo. "
02/01/2015 - "Further studies to assess the utility of ecallantide in patients with more severe angioedema may be useful. "
01/01/2013 - "Three patients with AAE were treated a total of 12 times with various dosing regimens of ecallantide based on the protocols established for the studies using ecallantide in HAE (Evaluation of DX-88's Effects in Mitigating Angioedema trials). "
02/01/2015 - "The addition of ecallantide to standard therapy does not appear to improve angioedema compared with placebo in ED patients with ACEIA. "
01/01/2015 - "In addition to its use as treatment for HAE, ecallantide has been used off label in the management of nonhistaminergic angioedema, not due to HAE. "
09/01/2013 - "Resolution of an acute attack of idiopathic angioedema with ecallantide."
|3.||Anaphylaxis (Anaphylactic Shock)
03/01/2015 - "The objective of this detailed retrospective data review was to characterize anaphylaxis cases within the ecallantide clinical trials database. "
01/01/2015 - "Due to the risk of anaphylaxis, ecallantide cannot be self-administered and must be given by a health care professional. "
01/01/2015 - "Ecallantide is generally a safe and well-tolerated medication; however, based on reports of anaphylaxis, ecallantide does contain a black box warning. "
01/01/2011 - "Although there is a small risk for anaphylaxis, which limits home administration, ecallantide is a novel, safe, effective and alternative treatment for acute HAE attacks."
01/01/2011 - "Owing to the risk of anaphylaxis, ecallantide should be administered by a health care professional. "
07/01/2011 - "Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials."
11/15/2011 - "Clinical data were reviewed for C1 inhibitor, ecallantide, and icatibant in the treatment of acute edema attacks caused by HAE. "
03/01/2015 - "Potential cases of hypersensitivity reactions in the ecallantide clinical development program were identified by examining reported adverse events. "
03/01/2015 - "Use of ecallantide has been associated with a risk of hypersensitivity reactions, including anaphylaxis. "
08/01/2010 - "The main safety concern following ecallantide treatment is hypersensitivity reactions, including anaphylaxis. "
03/01/2015 - "Among patients who received subcutaneous ecallantide (n = 230 patients; 1045 doses of 30 mg ecallantide), 8 patients (3.5%) had reactions that met the National Institute of Allergy and Infectious Disease criteria for anaphylaxis; none occurred on first exposure to the drug. "
|1.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|8.||sorafenib (BAY 43-9006)